Rapport Therapeutics, Inc. RAPP Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -28.3%— | —— | —— | —— | —— | |
| Return on invested capital | -38.2%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 27.1×+0.9× | 26.2×-10.2× | 36.4×+13.6× | 22.7×-8.3× | 31×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Per Share | ||||||
| Book value per share | $9.98-19.8% | $12.45-7.7% | $13.49+81.4% | $7.43-8.3% | $8.11-45.0% | |
| Valuation | ||||||
| Market capitalization | $1.5B+3.4% | $1.45B+5.6% | $1.37B+203% | $451.84M+23.4% | $366.06M— | |
| Price / book | 3.2×+0.2× | 3×+0.3× | 2.7×+1.0× | 1.7×+0.4× | 1.3×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Rapport Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.